BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33767588)

  • 21. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
    Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
    Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
    Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rutin attenuates Sorafenib-induced Chemoresistance and Autophagy in Hepatocellular Carcinoma by regulating BANCR/miRNA-590-5P/OLR1 Axis.
    Zhou M; Zhang G; Hu J; Zhu Y; Lan H; Shen X; Lv Y; Huang L
    Int J Biol Sci; 2021; 17(13):3595-3607. PubMed ID: 34512168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
    Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
    Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-26a-5p Inhibits Cell Proliferation and Enhances Doxorubicin Sensitivity in HCC Cells via Targeting AURKA.
    Yuan YL; Yu H; Mu SM; Dong YD; Li Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819851833. PubMed ID: 31570091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
    Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
    Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
    Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
    Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
    Meng W; Tai Y; Zhao H; Fu B; Zhang T; Liu W; Li H; Yang Y; Zhang Q; Feng Y; Chen G
    Med Sci Monit; 2017 Mar; 23():1295-1304. PubMed ID: 28291769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-26b-5p enhances T cell responses by targeting PIM-2 in hepatocellular carcinoma.
    Han W; Li N; Liu J; Sun Y; Yang X; Wang Y
    Cell Signal; 2019 Jul; 59():182-190. PubMed ID: 30593845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
    Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
    Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737.
    Zhao G; Wang T; Huang QK; Pu M; Sun W; Zhang ZC; Ling R; Tao KS
    World J Gastroenterol; 2016 Jun; 22(23):5364-73. PubMed ID: 27340352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentiviral-mediated microRNA-26b up-regulation inhibits proliferation and migration of hepatocellular carcinoma cells.
    Lin CZ; Ou RW; Hu YH
    Kaohsiung J Med Sci; 2018 Oct; 34(10):547-555. PubMed ID: 30309482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
    Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M
    Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
    Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.
    Cao Y; Zhang F; Wang H; Bi C; Cui J; Liu F; Pan H
    Mol Cell Biochem; 2021 Jan; 476(1):279-292. PubMed ID: 32965597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.